JAMES LOUIS RUBENSTEIN

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment
    James L Rubenstein
    Division of Hematology Oncology, Comprehensive Cancer Center, Cancer Research Institute, Department of Neurosurgery, UCSF, San Francisco, CA 94143, USA
    Blood 101:466-8. 2003
  2. ncbi Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma
    James L Rubenstein
    Division of Hematology Oncology and Helen Diller Comprehensive Cancer Center, University of California San Francisco, CA 94143, USA
    Blood 121:745-51. 2013
  3. ncbi Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI
    Matthew J Wieduwilt
    Division of Hematology Oncology, University of California San Francisco, Box 1270, 505 Parnassus Avenue, San Francisco, CA 94143, USA
    Clin Cancer Res 18:1146-55. 2012
  4. ncbi Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment
    James Rubenstein
    University of California, San Francisco, CA, USA
    Leuk Lymphoma 49:43-51. 2008
  5. ncbi Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma
    James L Rubenstein
    Division of Hematology Oncology, and the Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94143, USA
    J Clin Oncol 25:1350-6. 2007
  6. ncbi Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
    J L Rubenstein
    Division of Hematology Oncology, University of California, San Francisco, USA
    Neoplasia 2:306-14. 2000
  7. ncbi Gene expression and angiotropism in primary CNS lymphoma
    James L Rubenstein
    University of California, San Francisco, Division of Hematology Oncology M1282 Box 1270, 94143, USA
    Blood 107:3716-23. 2006
  8. ncbi Pathology and genetics of primary central nervous system and intraocular lymphoma
    James L Rubenstein
    Division of Hematology Oncology, University of California San Francisco, Room M1282, Box 1270, San Francisco, CA 94143, USA
    Hematol Oncol Clin North Am 19:705-17, vii. 2005
  9. ncbi Hemorrhage and VEGF expression in a case of primary CNS lymphoma
    James Rubenstein
    Division of Hematology Oncology, University of California, San Francisco 94143, USA
    J Neurooncol 58:53-6. 2002
  10. ncbi Protein biomarker identification in the CSF of patients with CNS lymphoma
    Sushmita Roy
    PPD Biomarker Discovery Sciences, LLC, Menlo Park, CA, USA
    J Clin Oncol 26:96-105. 2008

Research Grants

  1. Molecular Classification and Therapy of CNS Lymphomas
    James Rubenstein; Fiscal Year: 2007
  2. The Role of Interleukin-4 (IL-4) in the Pathogenesis of Non-Hodgkin's Lymphoma
    JAMES LOUIS RUBENSTEIN; Fiscal Year: 2010

Collaborators

Detail Information

Publications11

  1. ncbi Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment
    James L Rubenstein
    Division of Hematology Oncology, Comprehensive Cancer Center, Cancer Research Institute, Department of Neurosurgery, UCSF, San Francisco, CA 94143, USA
    Blood 101:466-8. 2003
    ..96 hours. A phase 1 study to investigate the safety and pharmacokinetics of intrathecal rituximab in patients with recurrent lymphomatous meningitis will be implemented based on these findings...
  2. ncbi Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma
    James L Rubenstein
    Division of Hematology Oncology and Helen Diller Comprehensive Cancer Center, University of California San Francisco, CA 94143, USA
    Blood 121:745-51. 2013
    ..KEY POINTS: Phase I study showed that intraventricular rituximab plus methotrexate is feasible and active in the treatment of refractory CNS lymphoma...
  3. ncbi Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI
    Matthew J Wieduwilt
    Division of Hematology Oncology, University of California San Francisco, Box 1270, 505 Parnassus Avenue, San Francisco, CA 94143, USA
    Clin Cancer Res 18:1146-55. 2012
    ..In addition, we evaluated the prognostic value of the minimum apparent diffusion coefficient (ADC(min)) derived from diffusion-weighted MRI (DW-MRI) in patients treated with this regimen...
  4. ncbi Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment
    James Rubenstein
    University of California, San Francisco, CA, USA
    Leuk Lymphoma 49:43-51. 2008
    ....
  5. ncbi Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma
    James L Rubenstein
    Division of Hematology Oncology, and the Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94143, USA
    J Clin Oncol 25:1350-6. 2007
    ..We therefore conducted a phase I dose-escalation study of intrathecal rituximab monotherapy in patients with recurrent CNS non-Hodgkin's lymphoma (NHL)...
  6. ncbi Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
    J L Rubenstein
    Division of Hematology Oncology, University of California, San Francisco, USA
    Neoplasia 2:306-14. 2000
    ....
  7. ncbi Gene expression and angiotropism in primary CNS lymphoma
    James L Rubenstein
    University of California, San Francisco, Division of Hematology Oncology M1282 Box 1270, 94143, USA
    Blood 107:3716-23. 2006
    ..High expression of activated STAT6 in tumors was associated with short survival in an independent set of patients with primary CNS lymphoma who were treated with high-dose intravenous methotrexate therapy...
  8. ncbi Pathology and genetics of primary central nervous system and intraocular lymphoma
    James L Rubenstein
    Division of Hematology Oncology, University of California San Francisco, Room M1282, Box 1270, San Francisco, CA 94143, USA
    Hematol Oncol Clin North Am 19:705-17, vii. 2005
    ..It is possible that insights gained from these studies will facilitate the development of targeted therapies, which address the fundamental genetic mutations that drive PCNSL and intraocular lymphoma growth...
  9. ncbi Hemorrhage and VEGF expression in a case of primary CNS lymphoma
    James Rubenstein
    Division of Hematology Oncology, University of California, San Francisco 94143, USA
    J Neurooncol 58:53-6. 2002
    ..This is the first report of VEGF expression in primary CNS lymphoma. The potential significance of VEGF expression with respect to the biology of this tumor is discussed...
  10. ncbi Protein biomarker identification in the CSF of patients with CNS lymphoma
    Sushmita Roy
    PPD Biomarker Discovery Sciences, LLC, Menlo Park, CA, USA
    J Clin Oncol 26:96-105. 2008
    ..Elucidation of the CSF proteome may yield insights into the pathogenesis of CNS disease. We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions...
  11. ncbi Molecular pathogenesis of primary central nervous system lymphoma
    Cigall Kadoch
    Department of Molecular and Cell Biology, University of California, Berkeley, CA, USA
    Neurosurg Focus 21:E1. 2006
    ..The authors discuss the current knowledge of the molecular pathogenesis of CNS lymphomas and review the recent advances in gene expression profile analysis and identification of novel prognostic biomarkers...

Research Grants4

  1. Molecular Classification and Therapy of CNS Lymphomas
    James Rubenstein; Fiscal Year: 2007
    ..We will perform gene expression profile analysis of these tumors from diagnostic specimens obtained from a frozen tumor bank to identify a set of genes, which can be used to predict outcome. ..
  2. The Role of Interleukin-4 (IL-4) in the Pathogenesis of Non-Hodgkin's Lymphoma
    JAMES LOUIS RUBENSTEIN; Fiscal Year: 2010
    ....